NK cells and the tumour microenvironment: Implications for NK-cell function and anti-tumour activity

Trends in Immunology

Volumn 24, Issue 11, 2003, Pages 603-609

  Albertsson, Per A ^a   Basse, Per H ^b   Hokland, Marianne ^c   Goldfarb, Ronald H ^d,e   Nagelkerke, J Fred ^f   Nannmark, Ulf ^g   Kuppen, Peter J K ^h  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF NORTH TEXAS   (United States)

^e Sopherion Therapeutics Inc   (United States)

^f LEIDEN UNIVERSITY   (Netherlands)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2; PROTEINASE;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CROSS LINKING; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; NATURAL KILLER CELL; REVIEW; TARGET CELL; TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0242302582     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.09.007     Document Type: Review

References (75)

1. Smyth M.J., et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer. 2:2002;850-861.
2. Colucci F., et al. What does it take to make a natural killer? Nat. Rev. Immunol. 3:2003;413-425.
3. Marincola F.M., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:2000;181-273.
4. Basse P.H. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. APMIS Suppl. 55:1995;1-28.
5. Sacchi M., et al. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Int. J. Cancer. 47:1991;784-791.
6. Hayakawa M., et al. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2. Urol. Int. 53:1994;117-124.
7. Ueda Y., et al. Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology. 46:(Suppl. 1):1999;1274-1279.
8. Vujanovic N.L., et al. Antitumor functions of natural killer cells and control of metastases. Methods. 9:1996;394-408.
9. Farag S.S., et al. New directions in natural killer cell-based immunotherapy of human cancer. Expert Opin. Biol. Ther. 3:2003;237-250.
10. Villegas F.R., et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 35:2002;23-28.
11. Ishigami S., et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 88:2000;577-583.
12. Coca S., et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 79:1997;2320-2328.
13. Hagenaars M., et al. Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses. Int. J. Cancer. 78:1998;783-789.
14. Hokland M., et al. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. In vivo. 13:1999;199-204.
15. Wei W.Z., et al. Natural killer activity of lymphocytic infiltrates in mouse mammary lesions. Br. J. Cancer. 55:1987;589-594.
16. Basse P., et al. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J. Exp. Med. 174:1991;479-488.
17. Basse P.H., et al. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J. Natl. Cancer Inst. 83:1991;944-950.
18. Hagenaars M., et al. The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy? Clin. Exp. Metastasis. 18:2000;189-196.
19. Yang Q., et al. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int. J. Cancer. 105:2003;512-519.
20. Nannmark U., et al. Morphological studies of effector cell-microvessel interactions in adoptive immunotherapy in tumor-bearing animals. Nat. Immunol. 15:1996;78-86.
21. Nannmark U., et al. Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy. Cancer Res. 55:1995;4627-4632.
22. Nannmark U., et al. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells. In vivo. 14:2000;651-658.
23. Melder R.J., et al. Modulation of A-NK cell rigidity: in vitro characterization and in vivo implications for cell delivery. Biorheology. 38:2001;151-159.
24. Hagenaars M., et al. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration. Int. J. Cancer. 75:1998;233-238.
25. Wiedle G., et al. A chimeric cell adhesion molecule mediates homing of lymphocytes to vascularized tumors. Cancer Res. 59:1999;5255-5263.
26. Yong K.L., et al. Influence of cell cycling and cell division on transendothelial migration of CD34+ cells. Br. J. Haematol. 119:2002;500-509.
27. Cooper M.A., et al. The biology of human natural killer-cell subsets. Trends Immunol. 22:2001;633-640.
28. dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 33:2003;119-124.
29. Robertson M.J. Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 71:2002;173-183.
30. Hanna, J. et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16 negative human natural killer cells. Blood (in press).
31. Beider, K. et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood (in press).
32. Umehara H., et al. Fractalkine and vascular injury. Trends Immunol. 22:2001;602-607.
33. Johnatty R.N., et al. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J. Immunol. 158:1997;2327-2333.
34. Timonen T. Natural killer cells: endothelial interactions, migration, and target cell recognition. J. Leukoc. Biol. 62:1997;693-701.
35. Carnaud C., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:1999;4647-4650.
36. Kelly J.M., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3:2002;83-90.
37. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2:2002;957-964.
38. Lardner A. The effects of extracellular pH on immune function. J. Leukoc. Biol. 69:2001;522-530.
39. Hellstrand K. Melanoma immunotherapy: a battle against radicals? Trends Immunol. 24:2003;232-233.
40. Zeng L., et al. Selective regulation of RNK-16 cell matrix metalloproteinases by the EP4 subtype of prostaglandin E2 receptor. Biochemistry. 35:1996;7159-7164.
41. Kitson R.P., et al. Matrix metalloproteinases produced by rat IL-2-activated NK cells. J. Immunol. 160:1998;4248-4253.
42. Kim M.H., et al. Secreted and membrane-associated matrix metalloproteinases of IL-2- activated NK cells and their inhibitors. J. Immunol. 164:2000;5883-5889.
43. Albertsson P., et al. Matrix metalloproteinases of human NK cells. In vivo. 14:2000;269-276.
44. Owen C.A., et al. The cell biology of leukocyte-mediated proteolysis. J. Leukoc. Biol. 65:1999;137-150.
45. Johansson B.R., et al. Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis. Nat. Immunol. 15:1996;87-97.
46. al-Atrash G., et al. IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochem. Biophys. Res. Commun. 292:2002;184-189.
47. al-Atrash G., et al. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion. In vivo. 14:2000;565-570.
48. Gellert G.C., et al. Urokinase-type plasminogen activator receptor crosslinking in an NK cell line increases integrin surface expression by the MAP kinase/ERK 1/2 signaling pathway. J. Cell. Biochem. 89:2003;279-288.
49. Chuang S.S., et al. 2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness. Immunology. 100:2000;378-383.
50. Yamamoto S., et al. ADAM family proteins in the immune system. Immunol. Today. 20:1999;278-284.
51. McCawley L.J., et al. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13:2001;534-540.
52. Jaaskelainen J., et al. Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. A study on adhesion molecules involved. J. Immunol. 149:1992;260-268.
53. Iwasaki K., et al. Infiltrative and cytolytic activities of lymphokine-activated killer cells against a human glioma spheroid model. Cancer Res. 50:1990;2429-2436.
54. Kuppen P.J., et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem. Cell Biol. 115:2001;67-72.
55. Johansson B.R., et al. Ultrastructure of interactions between activated murine natural killer cells and melanoma cells in an extracellular matrix (Matrigel) environment. Nat. Immunol. 15:1996;98-106.
56. Palmieri G., et al. Interaction of natural killer cells with extracellular matrix induces early intracellular signalling events and enhances cytotoxic functions. Nat. Immunol. 15:1996;147-153.
57. Somasundaram R., et al. Collagens serve as an extracellular store of bioactive interleukin 2. J. Biol. Chem. 275:2000;38170-38175.
58. Franitza S., et al. TNF-α associated with extracellular matrix fibronectin provides a stop signal for chemotactically migrating T cells. J. Immunol. 165:2000;2738-2747.
59. Buckley C.D., et al. Sticky moments with sticky molecules. Immunol. Today. 21:2000;601-603.
60. Grimm E.A., et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1982;1823-1841.
61. Herberman R.B., et al. Lymphokine-activated killer cell activity: characteristics of effector cells and their progenitors in blood and spleen. Immunol. Today. 8:1987;178-181.
62. Rosenberg S.A., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1985;1485-1492.
63. Law T.M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 76:1995;824-832.
64. Lotze M.T., et al. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology. 172:1986;420-437.
65. Weber J.S., et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 10:1992;33-40.
66. Kammula U.S., et al. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83:1998;797-805.
67. Liu K., et al. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167:2001;6356-6365.
68. Liu K., et al. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. 26:2003;190-201.
69. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 9:2003;269-277.
70. Trapani J.A., et al. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2:2002;735-747.
71. Stennicke H.R., et al. Caspases - controlling intracellular signals by protease zymogen activation. Biochim. Biophys. Acta. 1477:2000;299-306.
72. Kashii Y., et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 163:1999;5358-5366.
73. Waterhouse N.J., et al. CTL: Caspases Terminate Life, but that's not the whole story. Tissue Antigens. 59:2002;175-183.
74. Sarin A., et al. Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J. Immunol. 161:1998;2810-2816.
75. Yao L., et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 93:1999;1612-1621.